0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FOLR2

FOLR2

Brief Information

Name:Folate receptor beta
Target Synonym:FOLR1,FRbeta,Folate Receptor Alpha,FBP,Placental folate-binding protein,Folate receptor, fetal/placental,FOLR2,Folate receptor beta,Folate Receptor 2 (Fetal),Folate-Binding Protein, Fetal/Placental,BETA-HFR,FBP/PL-1,FR-Beta,FR-P3,Folate Receptor 2,FRβ
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

FO2-H82E8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Folic acid-BSA on CM5 Chip can bind Biotinylated Human FOLR2, His,Avitag (Cat. No. FO2-H82E8) with an affinity constant of 4.61 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

FO2-C52H8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Folic acid-BSA on CM5 Chip can bind Cynomolgus FOLR2 Protein, His Tag (Cat. No. FO2-C52H8) with an affinity constant of 1.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name

FOLR2,BETA-HFR,FBP,PL-1,FR-BETA,FR-P3,FBP

Background

Folate receptor beta is also known as Folate receptor 2, FBP, FOLR2, BETA-HFR, FBP/PL-1, FR-BETA, FR-P3, and is a member of the folate receptor (FOLR) family. and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. This protein has a 68% and 79% sequence homology with the FOLR1 and FOLR3 proteins, respectively. The FOLR2 protein was originally thought to exist only in placenta, but is also detected in spleen, bone marrow, and thymus. FOLR2 is predominantly expressed in placenta, cells of the neutrophilic lineage, and some CD34+ hematopoietic progenitor cells.  It is upregulated on myeloid leukemias, head and neck squamous cell carcinomas, and several nonepithelial cancers. It is also upregulated on macrophages and monocytes at chronic inflammatory sites including rheumatoid arthritis synovium and glioblastoma.  FOLR2 is a marker for macrophages generated in the presence of M-CSF, but not GM-CSF. Its expression correlates with increased folate uptake ability. Folate conjugates of therapeutic drugs are a potential immunotherapy tool to target tumor-associated macrophages.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
EC-1456 EC-1456; EC-0531 Phase 1 Clinical Novartis Pharma Ag Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Vintafolide EC-145; MK-8109 Phase 2 Clinical Novartis Pharma Ag Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
OTL-38 EC-17; OTL-38; OTL-0038; Pteroyl-L-Tyr-S0456 Phase 3 Clinical On Target Ovarian Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms Details

This web search service is supported by Google Inc.

totop